Loading...
01/09 22:53
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call presents a mixed picture: while there are positive developments such as improved cash position, strong gross margins, and strategic partnerships, there are also concerns about revenue decline, macroeconomic uncertainties, and reliance on enterprise health. The Q&A section did not alleviate these concerns, with management unable to provide clear guidance on certain issues. The lack of a share repurchase program further tempers positive sentiment. Given these factors, the likely stock price movement is neutral, within the -2% to 2% range over the next two weeks.
Revenue $3.4 million (down from $3.8 million), a decrease of approximately 10.5% year-over-year due to capital budget impacts from certain inpatient rehabilitation facilities related to the EksoNR Enterprise Health product.
Gross Profit $1.8 million with a gross margin of approximately 54% (up from $2 million and 52% margin), driven by cost savings in supply chain and a reduction in service costs, partially offset by lower margin sales related to increased volume through distribution.
Operating Expenses $5.3 million (essentially unchanged from $5.2 million), indicating stable operational costs year-over-year.
Net Loss $2.9 million or $0.12 per share (improved from a net loss of $3.4 million or $0.20 per share), reflecting a reduction in losses year-over-year.
Net Cash Used in Operations $2 million (down from $3.5 million), indicating improved cash flow management.
Cash and Restricted Cash $8.1 million (up from $6.5 million), showing an increase in liquidity year-over-year.
New Product Launch: Ekso has established a go-to-market strategy for the Ekso Indigo Personal exoskeleton, aimed at notifying early physician and provider adopters of the new CMS-benefit category redetermination.
Distribution Partnerships: Ekso announced Bionic P&O as a new distributor for the Indigo Personal exoskeleton, which has already submitted its first patient claim to Medicare.
Market Expansion: Ekso is focusing on expanding its market presence through partnerships with National Seating & Mobility and Bionic P&O, which will broaden access to the Indigo Personal exoskeleton.
Operational Efficiency: The company achieved a gross margin of approximately 54%, driven by cost savings in supply chain and a reduction in service costs.
Cash Management: Ekso reported a decrease in cash burn, using $2 million in net cash for operations in Q1 2025, down from $3.5 million in Q1 2024.
Strategic Shift: Ekso is shifting focus from its legacy enterprise business to a more scalable go-to-market strategy for personal health products, particularly the Indigo Personal exoskeleton.
Revenue Reduction: The company recorded a revenue decrease to $3.4 million in Q1 2025 from $3.8 million in Q1 2024, attributed to capital budget impacts from inpatient rehabilitation facilities affecting the EksoNR Enterprise Health product.
Macroeconomic Uncertainties: Several customers experienced temporary impacts on their capital budgets due to macroeconomic uncertainties, affecting the enterprise business.
Regulatory Changes: The establishment of a new CMS pricing determination for the Ekso Indigo Personal exoskeleton in Q2 2024 presents both an opportunity and a risk, as the company cannot guarantee that all pipeline candidates will result in claims submissions or payments.
Cash Burn: The company reported a net loss of $2.9 million in Q1 2025, indicating ongoing financial challenges despite a reduction in cash burn compared to the previous year.
Dependence on Enterprise Health: While there is a growing contribution from personal health products, the majority of revenue in 2025 is still expected to come from the Enterprise Health segment, indicating a risk of over-reliance on this segment.
Go-to-Market Strategy: Ekso Bionics has established a go-to-market strategy aimed at notifying early physician and provider adopters of the new CMS-benefit category redetermination for the Ekso Indigo Personal exoskeleton.
Distribution Network Expansion: The company has engaged PRIA Healthcare for market access services and announced Bionic P&O as a new distributor for the Indigo Personal exoskeleton.
Pipeline Development: Ekso has developed a pipeline of over 35 Medicare beneficiaries qualified for the Ekso Indigo Personal in 2025, a 37% increase from the previous quarter.
Scalable Programs Investment: The company is investing in scalable programs to increase contributions from personal health products throughout 2025.
Revenue Expectations: While the majority of revenue in 2025 will still come from Enterprise Health, Ekso anticipates rapidly increasing contributions from personal health products.
Financial Outlook: The company reported a net loss of $2.9 million for Q1 2025, with expectations of improved financial performance as the personal health segment grows.
Cash Position: As of March 31, 2025, Ekso had cash and restricted cash of $8.1 million, indicating a stronger cash position compared to $6.5 million at the end of 2024.
Share Repurchase Program: None
The earnings call highlighted several negative factors: a significant revenue decline, reduced gross profit and margins, and an increased net loss. The Q&A revealed deferred sales due to regulatory issues and uncertainty in Enterprise Health sales recovery. Despite some progress in the Indego Personal business and cost management efforts, the challenges in coding, coverage, and payment processes, alongside supply chain risks and AI integration uncertainties, contribute to a negative sentiment. The lack of clear guidance on grant reliance further exacerbates concerns, likely leading to a negative stock price reaction.
The earnings call presents a mixed picture: while there are positive developments such as improved cash position, strong gross margins, and strategic partnerships, there are also concerns about revenue decline, macroeconomic uncertainties, and reliance on enterprise health. The Q&A section did not alleviate these concerns, with management unable to provide clear guidance on certain issues. The lack of a share repurchase program further tempers positive sentiment. Given these factors, the likely stock price movement is neutral, within the -2% to 2% range over the next two weeks.
The earnings call presents a mixed outlook. Positive aspects include improved gross margins and reduced operating expenses, along with optimistic guidance for multi-unit orders in North America. However, the company missed EPS expectations and faces regulatory and market access challenges, which could temper investor enthusiasm. The lack of a share repurchase program and unclear timelines for private payer engagement further contribute to a neutral sentiment. The company's financial performance shows slight improvement, but not enough to strongly impact the stock price positively or negatively.
The earnings call presents mixed signals: improved financial metrics, optimistic guidance, and expanding market presence are positive, but offset by regulatory uncertainties, competitive pressures, and supply chain risks. The lack of a share repurchase program and unclear management responses in the Q&A session further contribute to a cautious outlook. With no new partnerships or strong catalysts, the stock is likely to remain stable, resulting in a neutral sentiment.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
